• Policy
• Generics for Janumet competition begins in earnest in Oct.
• by Lee, Tak-Sun Sep 21, 2023 05:23am

• Policy
• High-priced drugs need adjustment from the approval stage
• by Lee, Tak-Sun Sep 20, 2023 05:36am

• Policy
• The NHIS begins negotiations to increase the size of PSE
• by Lee, Tak-Sun Sep 20, 2023 05:36am

• Policy
• Reimbursement imminent for some anticancer drugs in KOR
• by Lee, Tak-Sun Sep 20, 2023 05:35am

• Policy
• MFDS starts review on phenylephrine after FDA advisory decis
• by Lee, Hye-Kyung Sep 19, 2023 05:42am

• Policy
• Januvia generics up for insurance price cuts… 119 combinati
• by Lee, Tak-Sun Sep 19, 2023 05:41am

• Policy
• Olumiant re-examination period extended by 35 months
• by Lee, Hye-Kyung Sep 18, 2023 05:26am

• Policy
• Super-antibiotic Tygacil reauthorized for use in Korea
• by Lee, Tak-Sun Sep 18, 2023 05:26am

• Policy
• Authorization rate for No.16 is still 0%
• by Lee, Hye-Kyung Sep 18, 2023 05:26am

• Policy
• Celltrion receives approval for Nesina Met SR
• by Lee, Hye-Kyung Sep 15, 2023 05:33am